ARCHIVES

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

Kessler Promises Cancer Patient Liaison In FDA; Considers Joint Drugs, Biologics Oncology Review

August 14, 1992

DeVita Says Payline Compression Leading to More Decisions By Staff On Funding

June 28, 1985

Judge Declines To Issue Injunction To Stop Amgen’s “Bundling.”

December 1, 2006

UICC Grant Programs Available To Support International Activities

April 16, 1976

In Congress: HHS Hasn’t Identified Another Source For NIH Increase If Tobacco Bill Not Passed: Shalala

March 6, 1998

DCE Board Approves Concepts For New Chemoprevention Groups, Retroviral Vaccine Research, Biochemical Markers, Feline Virus Studies

March 15, 1985